AQR Capital Management
TELO icon

AQR Capital Management’s Telomir Pharmaceuticals TELO Stock Holding History

AQR Capital Management’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,234
Closed -$41.5K – 3617
2025
Q2 		$41.5K Buy
+33,234
New +$76.8K ﹤0.01% 3247

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management's TELO Position: Q3 2025 in Review

AQR Capital Management sold out of Telomir Pharmaceuticals (TELO) in Q3 2025, closing a stake of 33,234 shares — an estimated $41.5K sold.

AQR Capital Management first reported a position in TELO in Q2 2025 and held it in 1 quarter. The position peaked at $41.5K in Q2 2025. 32 funds tracked by Wall St. Rank hold TELO as of Q3 2025.

  • AQR Capital Management reported no remaining Telomir Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 33,234 Telomir Pharmaceuticals shares in Q3 2025, an estimated $41.5K.
  • AQR Capital Management first reported a position in Telomir Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • AQR Capital Management's Telomir Pharmaceuticals position peaked at $41.5K in Q2 2025.
  • 32 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.